Takeaways: The approval of Nduvra (tapinarof) 1% for moderate to severe atopic dermatitis gives Organon a first‑in‑class, steroid‑free topical that can be prescribed by family physicians w...
Takeaways: Health Canada’s approval of Imcivree (setmelanotide) for acquired hypothalamic obesity (HO) gives Rhythm Pharmaceuticals its first targeted therapy in Canada for this rare, injury‑dri...
Takeaways: Health Canada’s authorization of the XFG‑adapted Comirnaty vaccine for the 2026–2027 season keeps Pfizer/BioNTech aligned with national recommendations to match contemporary Omicron l...
Takeaways: Sandoz Canada’s Health Canada authorization for PrSandoz Semaglutide, a generic version of Ozempic, gives the country its first lower‑cost semaglutide option for type 2 diabetes...
Takeaways: The C-POST data – 68% reduction in recurrence or death versus placebo – gives Regeneron a strong clinical story to push Libtayo earlier in the treatment pathway,...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Takeaways: The main market signal is strategic rather than commercial: Health Canada’s clearance, alongside PHAC’s collaboration with Moderna, helps de-risk the company’s mRNA infectious-disease...
Takeaways: The approval expands Biocon’s immunology footprint in Canada by rounding out the Yesintek portfolio with an autoinjector alongside the already-approved prefilled syringe, vi...
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways: Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply co...
